Nautilus Biotechnolgy (NAUT) Stock Analysis & Winston Score
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Winston Score: 34/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (10/30)
- Growth: Mixed (7/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $0.95
Market Cap: $121M
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
